Nature Medicine, Published online: 08 November 2026; doi:10.1038/s41591-026-04787-8
As presented at the 2026 AHA Scientific Sessions, a cardiac magnetic resonance substudy of the CAMEO-SEMA trial showed that semaglutide significantly improved cardiac structure and function, including left atrial reservoir strain and left ventricular filling dynamics, in individuals with heart failure with preserved ejection fraction and obesity.
